左西孟旦在儿童心脏术后VA-ECMO撤机中的作用
本研究为观察性研究,比较心脏术后需VA-ECMO的儿童中,撤机前使用左西孟旦者与未使用者的结局。经双稳健估计调整协变量后,左西孟旦与撤机失败风险降低(aRR 0.20,95%CI 0.07-0.57)及院内死亡风险降低(aRR 0.45,95%CI 0.26-0.76)相关。
要点
- 心脏术后VA-ECMO儿童撤机前使用左西孟旦与撤机失败风险降低相关。
- 左西孟旦使用与院内死亡风险降低相关(aRR 0.45)。
- 需前瞻性研究确认因果,当前证据来自单中心观察性数据。
核心结论
- 心脏术后需VA-ECMO的儿童中,撤机前使用左西孟旦与撤机失败风险降低及院内死亡风险降低相关。
研究设计与样本
- 观察性研究,比较心脏术后需VA-ECMO并接受左西孟旦撤机与未接受者的结局。
- 2012年1月至2018年12月共118名 eligible 儿童,145次ECMO运行。
- 采用双稳健估计(IPTW联合回归调整)平衡协变量,最终模型进一步调整ECMO时长。
主要发现
- ECMO适应证:CPB撤机失败67/145(46%),低心排30/145(21%),ECPR 47/145(32%),其他1例。
- 54/145(37%)次ECMO运行在撤机前使用左西孟旦,ECMO置管后至开始左西孟旦的中位时间为39小时(IQR 14-83)。
- 未调整撤机失败率:左西孟旦组7%(4/54) vs 对照组19%(17/91)。
- 调整后左西孟旦与撤机失败风险降低相关(aRR 0.20,95%CI 0.07-0.57)。
- 调整后左西孟旦与院内死亡风险降低相关(aRR 0.45,95%CI 0.26-0.76)。
临床怎么用
- 对于心脏术后VA-ECMO撤机困难的儿童,可考虑在撤机前使用左西孟旦以降低撤机失败风险。
- 左西孟旦的使用时机多在ECMO置管后中位39小时,需结合血流动力学个体化决策。
局限性
- 为观察性研究,存在未测量混杂可能,不能确立因果关系。
- 单中心数据,样本量有限,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Levosimendan use is associated with more successful decannulation from veno-arterial extracorporeal membrane oxygenation (VA ECMO) in adults. We sought to determine the role of levosimendan in children who required VA ECMO after cardiac surgery. METHODS: This observational study compares the outcomes of children who required VA ECMO after cardiac surgery and received levosimendan for weaning with those who did not receive the drug. A doubly robust estimation methodology (inverse probability of treatment weighting with regression adjustment) was used to balance study covariates (age, weight, sex, lactate pre-ECMO, vasoactive-inotropic score pre-ECMO, ECMO indication, ECMO modality, Risk Adjustment for Congenital Heart Surgery-1 category), and the final model was further adjusted for duration of ECMO. RESULTS: Between January 2012 and December 2018, 118 eligible children received 145 ECMO runs [failed weaning from cardiopulmonary bypass, 67/145 (46%); low cardiac output state, 30/145 (21%); extracorporeal cardiopulmonary resuscitation, 47/145 (32%); other reasons in 1]. Levosimendan was administered before decannulation in 54/145 (37%) runs. The median time to start levosimendan after ECMO cannulation was 39 h (interquartile range, 14-83 h). The unadjusted rates of weaning failure in the levosimendan vs control group were 7% (4/54) vs 19% (17/91). In the controlled analysis, levosimendan was associated with decreased risk of weaning failure [adjusted relative risk (95% confidence interval), 0.20 (0.07-0.57)] and decreased risk of in-hospital mortality [adjusted relative risk (95% confidence interval), 0.45 (0.26-0.76)]. CONCLUSIONS: Levosimendan administration in children requiring VA ECMO after cardiac surgery was associated with decreased risk of weaning failure and decreased in-hospital mortality.
引用
- Pan KC, Shankar S, Millar J, et al. Role of levosimendan in weaning children requiring veno-arterial extracorporeal membrane oxygenation after cardiac surgery. Eur J Cardiothorac Surg. 2021. PMID: 32910173. doi:10.1093/ejcts/ezaa275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。